Evidence map›Paper›PMID 38757395›Full record

ArticleESC heart failure2024

Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.

Gabriela Neculae, Robert Adam, Andreea Jercan, Sorina Bădeliță, Catherina Tjahjadi, Mirela Draghici, Claudiu Stan, Jeroen J Bax, Bogdan A Popescu, Nina Ajmone Marsan and 2 more

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Role of Troponins in CardioOncology.Current treatment options in oncology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabriela NeculaeCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Robert AdamCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Andreea JercanCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Sorina BădelițăDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Catherina TjahjadiDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Mirela DraghiciDepartment of Neurology, Fundeni Clinical Institute, Bucharest, Romania.
Claudiu StanDepartment of Nuclear Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Jeroen J BaxDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Bogdan A PopescuCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Nina Ajmone MarsanDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Daniel CoriuCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Ruxandra JurcuțCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.ORCID 0000-0002-3438-2612

Funding

Pfizer Competitive Grant Program 1214/23.05.2023Pfizer Competitive Grant Program 2480/14.05.2020
6 · The paper itself

Abstract

aimsSystemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. METHODS AND

resultsWe prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 ± 13.9 vs. 60.2 ± 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97-4218.5) vs. AL 8024 ng/L (3058-14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4-20) vs. AL 78 ng/L (32-240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8-105.3) vs. AL: 68.4 mL/min (47.8-87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: -13.1% ± 3.5 vs. AL: -9.1% ± 4.3 P = 0.04), RV strain (ATTR: -21.9% ± 6.2 vs. AL: -16.8% ± 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% ± 12 vs. AL: 13.6% ± 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%.

conclusionsCA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.

Indexed as

CardiomyopathiesAgedAmyloid Neuropathies, FamilialBiomarkersDiagnosis, DifferentialEchocardiographyElectrocardiographyFemaleHumansImmunoglobulin Light-chain AmyloidosisMagnetic Resonance Imaging, CineMaleMiddle AgedPrealbuminProspective StudiesBiomarkersPrealbuminAL amyloidosisATTR amyloidosisCardiac amyloidosisDiagnostic scoreMyocardial deformation

Identifiers

PMID38757395
PMCPMC11424370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.